Professor Peter Leedman
Professor Peter Leedman studied medicine in Perth before travelling to Melbourne to complete training in endocrinology. He completed his PhD at the Walter and Eliza Hall Institute in Melbourne before completing a Post-Doctoral Fellowship at Harvard Medical School. He returned to Perth in the mid-90s as an academic and became the Director of the Harry Perkins Institute of Medical Research in 2014. He is recognised internationally for his research in the field of RNA biology and developing RNA-therapeutics to treat hormone-dependent and liver cancer. He co-founded a start-up company miReven in order to commercialise a novel microRNA therapy for poor prognostic solid cancers. He is also the Chairman of the Board of Linear Clinical Research Ltd a 24-bed early phase clinical trials suite owned by the Perkins.